Microbial Tryptamine as a Causative Cofactor of Incurable Cell Death Diseases of Unknown Etiology : The Cost of Related Healthcare in the US and Worldwide

Paley, Elena L.

Academic Press Inc（2026/04発売）

• 製本 Paperback:紙装版/ペーパーバック版／ページ数 300 p.
• 言語 ENG
• 商品コード 9780443276422

Full Description

Microbial tryptamine as a causative cofactor of incurable cell death diseases of unknown etiology: The cost of related healthcare in the US and worldwide investigates microbial tryptamine and its role in a range of diseases, such as Alzheimer's disease and Parkinson's disease, while also examining the economic burden of these conditions on healthcare systems globally. The book begins with an examination of microbial tryptamine's significance across neurodegenerative diseases, cancers and gastrointestinal conditions. It covers the implications of tryptamine in cell and organ transplantation, as well as the roles of diet and environment in tryptamine-induced disease progression. Additionally, the latest advances in treatment and prevention are considered. It then provides a critical analysis of expenditure on diseases related to tryptamine-induced cell toxicity and neurodegeneration, alongside an evaluation of current funding and market analysis. Following this, the author delves into research-related issues that may hinder biomedical progress, such as competition, plagiarism, and retractions of funded peer-reviewed articles. Collaboration between researchers and medical doctors is also examined. The book concludes with the author's own personal narrative and recommendations, emphasizing the need for open discussions to drive urgent changes in biomedical research funding and review processes. This book is suitable for biomedical experts and advanced students working with microbial tryptamine, as well as relevant funding agencies, aiming to spark discussion concerning the necessary reforms in funding priorities and practices related to research on microbial tryptamine and its significance for disease.

Contents

Part 1. Microbial tryptamine in diseases
1. Introduction: Contamination of food products with microbes producing cytotoxic tryptamine that induces gut dysbiosis
2. Differential abundance of tryptamine and related human gut microbial NQR sequence (ADAS) in cancers of gastrointestinal (GI) system and neurodegenerative diseases, spending budgets
3. Tryptamine in cell and organ transplantation
4. The roles of the diet and environment in the start and progression of diseases
5. Tryptamine-induced diseases: Future of biomedicine in saving lives by testing, preventing and treating the preventable/avoidable and modifiable medical conditions

Part 2. Expenditure and research funding
6. Expenditure on diseases related to tryptamine-induced cell toxicity and neurodegeneration
7. Funding of research projects and market analysis for diseases related to tryptamine

Part 3. Research-related issues interfering with the progress in the biomedical project
8. Competition, plagiarism and profit-driven motives in science
9. Massive retractions of funded articles is a symptom of serious failures in research funding
10. How do biology doctors and medical doctors - clinicians collaborate?

Part 4. A personal narrative and conclusive remarks
11. About the Author
12. Conclusions